Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2019
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance metrics. The following transaction details are provided:
- Funds Raised: $2.0 million
- Shares Issued: 1,369,863 shares of Class A common stock
- Price Per Share: $1.46
- Investor: MacAndrews & Forbes Group LLC
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The material change reported is the execution of a definitive agreement under the September 2019 Letter Agreement. The Company exercised its right to require the Investor to purchase the specified shares, resulting in an immediate increase in equity capital and outstanding share count.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the September 2019 Letter Agreement filed as Exhibit 10.1 to the Company's Form 10-Q for the quarter ended September 30, 2019.
Investor Verification Checklist
- Verify the terms of the September 2019 Letter Agreement (Exhibit 10.1 to the Q3 2019 10-Q) to understand future purchase obligations or rights.
- Confirm the dilution impact of the 1,369,863 newly issued shares on existing shareholders.
- Review the Company's most recent 10-Q or 10-K for current cash position and burn rate to assess the utility of the $2.0 million raise.
- Check for any subsequent filings regarding the use of proceeds from this transaction.